This article describes the surveillance schemes that are routinely reported on in Communicable Diseases Intelligence (CDI).

Communicable disease surveillance in Australia operates at the national, state and local levels. Primary responsibility for public health action lies with the state and territory health departments. The role of communicable disease surveillance at a national level includes:

• detecting outbreaks and identifying national trends;
• guidance for policy development and resource allocation at a national level;
• monitoring the need for and impact of national disease control programs;
• coordination of response to national or multi-jurisdictional outbreaks;
• description of the epidemiology of rare diseases, that occur infrequently at state and territory levels;
• meeting various international reporting requirements, such as providing disease statistics to the World Health Organization; and
• support for quarantine activities, which are the responsibility of the national government.

State and territory health departments collect notifications of communicable diseases under their public health legislation. In September 2007, the National Health Security Act 2007 (National Health Security Act, No 174) received royal assent. This Act provides a legislative basis for and authorises the exchange of health information, including personal information, between jurisdictions and the Commonwealth. The Act provides for the establishment of the National Notifiable Diseases List (NNDL), which specifies the diseases about which personal information can be provided. The National Health Security Agreement, which was drafted in 2007 and signed by Health Ministers in April 2008, establishes operational arrangements to formalise and enhance existing surveillance and reporting systems, an important objective of the Act. States and territories voluntarily forward de-identified data on a nationally agreed set of communicable diseases to the Department of Health and Ageing for the purposes of national communicable disease surveillance.

Surveillance has been defined by the World Health Organization as the ‘continuing scrutiny of all aspects of the occurrence and spread of disease that are pertinent to effective control.’ It is characterised by ‘methods distinguished by their practicability, uniformity, and frequently by their rapidity, rather than complete accuracy.’ Although some surveillance schemes aim for complete case ascertainment, others include only a proportion of all cases of the conditions under surveillance, and these samples are subject to systematic and other biases. Results generated from surveillance schemes must be interpreted with caution, particularly when comparing results between schemes, between different geographical areas or jurisdictions and over time. Surveillance data may also differ from data on communicable diseases gathered in other settings.

The major features of the surveillance schemes for which CDI publishes regular reports are described below.


National Notifiable Diseases Surveillance System

National compilations of notifiable diseases have been published intermittently in a number of publications since 1917. The National Notifiable Diseases Surveillance System (NNDSS) was established in 1990 under the auspices of the Communicable Diseases Network Australia (CDNA).

Sixty-five communicable diseases agreed upon nationally are reported to NNDSS, although not all 65 are notifiable in each jurisdiction. Data are sent electronically from states and territories daily or several times a week. The system is complemented by other surveillance systems, which provide information on various diseases, including four that are not reported to NNDSS (AIDS, HIV, and the classical and variant forms of Creutzfeldt-Jakob disease).

The NNDSS core dataset includes data fields for a unique record reference number; notifying state or territory; disease code; age; sex; Indigenous status; postcode of residence; date of onset of the disease; death, date of report to the state or territory health
department and outbreak reference (to identify cases linked to an outbreak). Where relevant, information on the species, serogroups/subtypes and phage types of organisms isolated, and on the vaccination status of the case is collected. Data quality is monitored by DoHA and the National Surveillanced Committee (NSC) and there is a continual process of improving the national consistency of communicable disease surveillance.

While not included in the core national dataset, enhanced surveillanced information for some diseases (hepatitis B [newly acquired], hepatitis C [newly acquired], invasive pneumococcal disease and tuberculosis) is obtained from states and territories.


Data are published in CDI every quarter and in an annual report. The reports include numbers of notifications for each disease by state and territory, and totals for Australia for the current period, the year to date, and for the corresponding period of the previous year. The national total for each disease is compared with the average number of notifications over the previous 5 years in the same period. A commentary on the notification data is included with the tables in each issue of CDI and graphs are used to illustrate important aspects of the data.

**Australian Childhood Immunisation Register**

Accurate information on the immunisation status of children is needed at the community level for program management and targeted immunisation efforts. A population-based immunisation register can provide this need. The Australian Childhood Immunisation Register (ACIR) commenced operation on 1 January 1996 and is now an important component of the Immunise Australia Program. It is administered and operated by Medicare Australia. The Register was established by transferring data on all children under the age of 7 years enrolled with Medicare to the ACIR. This constitutes a nearly complete population register, including approximately 99% of children who are registered with Medicare by 12 months of age. Analysis of coverage is undertaken 3 months after the due date for completion of each milestone, so that time is available for processing notifications and the impact on coverage estimates of delayed notification to the ACIR is minimised. Only children enrolled with Medicare are included in order to minimise inaccuracies in coverage estimates due to duplicate records.

Medicare Australia coverage reports for the 3 milestones are published in CDI each quarter. Coverage estimates are provided for each state and territory and Australia as a whole and for each individual vaccine assessed at each milestone. Changes in ‘fully immunised’ coverage from the previous quarter are also included in the tables.

A commentary on ACIR immunisation coverage estimates is included with the tables in each issue and graphs are used to provide trends in immunisation coverage.

An Immunisation Coverage Report is also published in CDI on an annual basis and provides more detailed data on immunisation coverage for all recommended vaccines by age group which are funded by the Immunise Australia Program, timeliness of immunisation, small area coverage estimates and data on conscientious objection to immunisation.

**Australian Gonococcal Surveillance Programme**

The Australian Gonococcal Surveillance Programme (AGSP) is a continuing program to monitor antimicrobial resistance in Neisseria gonorrhoeae and includes the reference laboratories in all states and territories. These laboratories report data on sensitivity to an agreed core group of antimicrobial agents on a quarterly basis and provide an expanded analysis as an annual report in CDI (Commun Dis Intell 2010;34(2):89–95). The antibiotics that are currently routinely surveyed are the penicillins, ceftriaxone, ciprofloxacin and spectinomycin, all of which are administered as single dose regimens. One main purpose of the AGSP is to help define standard protocols for antibiotic treatment of gonococcal infection. When in vitro resistance to a recommended agent is demonstrated in 5% or more of isolates, it is usual to reconsider the inclusion of that agent in current treatment schedules. Additional data are also provided.
on other antibiotics from time to time. At present all laboratories also test isolates for the presence of high level resistance to the tetracyclines and intermittent surveys of azithromycin resistance are conducted. Comparability of data is achieved by means of a standardised system of MIC testing and a program-specific quality assurance process.

**Australian Meningococcal Surveillance Programme**

The reference laboratories of the Australian Meningococcal Surveillance Programme report data of laboratory-confirmed cases confirmed either by culture or by non-culture techniques. Culture-positive cases where a Neisseria meningitidis is grown from a normally sterile site or skin, and non-culture based diagnoses, derived from results of nucleic acid amplification assays and serological techniques are defined as invasive meningococcal disease (IMD) according to Public Health Laboratory Network definitions.

Data are reported annually and quarterly in CDI. Data in the quarterly reports are restricted to a description of the number of cases per jurisdiction, and serogroup where known. A full analysis of laboratory-confirmed cases of IMD, including phenotyping and antibiotic susceptibility data are published annually (Commun Dis Intell 2010;33(3):291–302).

**Australian Paediatric Surveillance Unit**

The Australian Paediatric Surveillance Unit (APSU) is an active surveillance mechanism for prospective, national identification and study of children (< 15 years) with uncommon conditions of childhood, including rare infectious and vaccine preventable diseases, genetic disorders, child mental health problems, and rare injuries. Each month the APSU sends an e-mail or paper report card to approximately 1,330 paediatricians and other child health clinicians. Clinicians are asked to indicate whether or not they have seen a child newly diagnosed with any of the listed conditions. Clinicians reporting cases are asked to provide details about demographics, diagnosis, treatments and short-term outcomes. All negative and positive reports are logged into a database and the report card return rate has been maintained at over 90% over the last 17 years.

Communicable diseases currently under surveillance include: acute flaccid paralysis (to identify potential cases of poliovirus infection); congenital cytomegalovirus infection; congenital rubella; perinatal exposure to HIV and HIV infection, neonatal herpes simplex virus infection; neonatal varicella, congenital varicella, severe complications of varicella.

After demonstrating feasibility in 2007, APSU has conducted surveillance for severe complications of influenza during the influenza season each year. In 2009 APSU contributed to the national surveillance effort during the Influenza H1N1 09 pandemic.

APSU is a unit of the Royal Australasian College of Physicians, Paediatrics and Child Health Division and its activities are supported by the Department of Health and Ageing; Sydney Medical School, The University of Sydney; NHMRC Enabling Grant No: 402784, Practitioner Fellowship No: 457084, E. Elliott, and H1N1 Grant no: 630328; the Creswick Foundation Fellowship (Y Zurynski), and Kids Research Institute at the Children’s Hospital at Westmead.

For further information please contact the APSU Director, Professor Elizabeth Elliott on telephone: +61 2 9845 3005, facsimile +61 2 9845 3082 or email: apsu@chw.edu.au; Internet: www.apsu.org.au

**Australian National Creutzfeldt-Jakob Disease Registry**

The surveillance for CJD in Australia is conducted through the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). CJD has been scheduled as a notifiable disease in all Australian states and territories. The ANCJDR is under contract to the Commonwealth to identify and investigate all suspect cases of transmissible spongiform encephalopathies (TSE) in Australia. An annual update is published in CDI (Commun Dis Intell 2010;34(1):96–101).

**Australian Sentinel Practice Research Network**

The Royal Australian College of General Practitioners and the Department of General Practice at the University of Adelaide operate the Australian Sentinel Practices Research Network (ASPREN). ASPREN is a national network of general practitioners who report presentations of defined medical conditions each week. The main aims of ASPREN are to provide an indicator of the burden of disease in the primary health care setting and to act as an early warning indicator in the event of an influenza pandemic.

The list of conditions is reviewed annually by the ASPREN management committee and an annual report is published. In 2011, 4 conditions are being monitored; all of which are related to communicable diseases. These include influenza like illness, gastroenteritis, chickenpox and shingles.

Laboratory testing of ILI cases was implemented in 2010, allowing for viral testing of 25% of ILI patients for a range of respiratory viruses including influenza A, influenza B and H1N1(2009).
There are currently 170 general practitioners registered the network from all jurisdictions. Sixty-one per cent of these are in metropolitan areas, 29% in rural and 10% in remote areas of Australia. Approximately 9,000 consultations are recorded each week.

Data for communicable diseases are published in CDI every quarter. Data are presented in graphic format as the rate of reporting per 1,000 consultations per week. The conditions are defined as follows:

**Influenza-like illness – record once only per patient**

Must have the following: fever, cough and fatigue

**Gastroenteritis – record once only per patient**

Three or more loose stools, and/or 2 vomits in a 24 hour period excluding cases who have a known cause, for example bowel disease, alcohol, pregnancy.

**Chickenpox – record once only per patient**

An acute, generalised viral disease with a sudden onset of slight fever, mild constitutional symptoms and a skin eruption which is maculopapular for a few hours, vesicular for three to 4 days and leaves a granular scab.

**Shingles – record once only per patient**

Recurrence, recrudescence or re-activation of chickenpox infection. Vesicles with any erythematous base restricted to skin areas supplied by sensory nerves of a single or associated group of dorsal root ganglia. Lesions may appear in crops in irregular fashion along nerve pathways, are usually unilateral, deeper seated and more closely aggregated than those of chickenpox.

Note: Those conditions which show ‘record once only per patient’ are to have each occurrence of the condition only recorded on 1 occasion no matter how many patient contacts are made for this condition. If the condition occurs a second or subsequent time, it is to be recorded again. Conversely, for other conditions each attendance at which they are addressed in some way is to be recorded.

**HIV and AIDS surveillance**

National surveillance for HIV and AIDS is coordinated by the National Centre in HIV Epidemiology and Clinical Research (NCHECR), in collaboration with state and territory health authorities, the Australian Government Department of Health and Ageing, the Australian Institute of Health and Welfare and other collaborating networks in surveillance for HIV/AIDS.

Cases of HIV infection are notified to the National HIV Registry on the first occasion of diagnosis in Australia, either by the diagnosing laboratory (Australian Capital Territory and Tasmania), by doctor notification (Western Australia) or by a combination of laboratory and doctor sources (New South Wales, Northern Territory, Queensland, South Australia and Victoria). Cases of AIDS are notified through the state and territory health authorities to the National AIDS Registry. Diagnoses of both HIV infection and AIDS are notified with the person’s date of birth and name code, to minimise duplicate notifications while maintaining confidentiality.

Currently, 2 tables presenting the number of new diagnoses of HIV infection, AIDS and deaths following AIDS are published in each issue of CDI. The tabulations are based on data available 3 months after the end of the reporting period, to allow for reporting delay and to incorporate newly available information.

Each year from 1997, the NCHECR has published the HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia Annual Surveillance Report. The annual surveillance report, available through www.nchecr.unsw.edu.au, provides a comprehensive analysis and interpretation of surveillance data on HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. The report Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: Surveillance and Evaluation Report has been published from 2007, as an accompanying document to the Annual Surveillance Report. The Surveillance and Evaluation Report provides detailed analysis and interpretation of the occurrence of these infections in Aboriginal and Torres Strait Islander communities in Australia.

**Laboratory Virology and Serology Reporting Scheme**

The Laboratory Virology and Serology Reporting Scheme (LabVISE) began operating in 1977. The scheme currently comprises 17 laboratories from all states and the Australian Capital Territory. Contributors submit data fortnightly on the laboratory identification of viruses and other organisms. Each record includes mandatory data fields (laboratory, specimen collection date, a patient identifier code and organism), and optional fields (patient’s sex, date of birth or age, postcode of residence, specimen source, clinical diagnosis and the method of diagnosis). Reports are collated, analysed and published quarterly in CDI. Each report includes summary tables of total numbers of organisms identified by state or territory and numbers of reports by month and participating laboratory. Monthly updates of LabVISE data are also published on the Communicable Diseases Surveillance website.
LabVISE data should be interpreted with caution. The number and type of reports received are subject to a number of biases. These include the number of participating laboratories, which has varied over time. The locations of participating laboratories also create bias, as some jurisdictions are better represented than others. Also changes in diagnostic practices, particularly the introduction of new testing methodologies, may affect laboratory reports. The ability of laboratory tests to distinguish acute from chronic or past infection must also be considered in interpretation of the data. Although changes in incidence cannot be determined with precision from this data, general trends can be observed, for example with respect to seasonality and the age-sex distribution of patients. (Review in Commun Dis Intell 2002;26(4):323–374).

**National Influenza Surveillance Scheme**

Influenza surveillance in Australia is based on several schemes collecting a range of data that can be used to measure influenza activity.

- Since 2001, laboratory-confirmed influenza has been a notifiable disease in all Australian states and territories (except South Australia) and reported in the National Notifiable Diseases Surveillance System.
- In 2009, 6 sentinel general practitioner schemes contribute reports of influenza-like illness: the Australian Sentinel Practice Research Network, the Tropical Influenza Surveillance from the Northern Territory, the New South Wales Sentinel General Practice Scheme, the Victorian Sentinel General Practice Scheme, Queensland and Western Australian sentinel general practices.
- The Laboratory Virology and Serology Reporting Scheme laboratory reports of influenza diagnoses including virus type.
- The results of each of the schemes are published together fortnightly throughout the influenza season (May to October) on the department’s web site as the Australian Influenza Report.

Annual reports on influenza in Australia are published in CDI each year (Commun Dis Intell 2010;34(1):8–22). These reports include the above data as well as absenteeism data from a major national employer, hospitalisation and mortality data and influenza typing data from the WHO Collaborating Centre for Influenza Reference and Research.

**OzFoodNet: enhanced foodborne disease surveillance**

The Australian Government Department of Health and Ageing established the OzFoodNet network in 2000 to collaborate nationally in the investigation of foodborne disease. OzFoodNet conducts studies on the burden of illness and coordinates national investigations into outbreaks of foodborne disease.

OzFoodNet reports quarterly on investigations of gastroenteritis outbreaks and clusters of disease potentially related to food. Annual reports have been produced and published in CDI (Commun Dis Intell 2010;34(4):396–426) since 2001. Data are reported from all Australian jurisdictions.

**Sentinel Chicken Surveillance Programme**

The Sentinel Chicken Surveillance Programme is used to provide an early warning of increased flavivirus activity in Australia. The main viruses of concern are Murray Valley encephalitis (MVEV) and Kunjin viruses. MVEV causes the disease Murray Valley encephalitis (formerly known as Australian encephalitis), a potentially fatal disease in humans. Encephalitis is less frequent in cases of Kunjin virus infection and these encephalitis cases have a lower rate of severe sequelae.

These viruses are enzootic in parts of the north-east Kimberley region of Western Australia and the Top End of the Northern Territory but are epizootic in other areas of the Kimberley, Pilbara, Gascoyne Murchison and Mid-west regions of Western Australia, in north Queensland and in Central Australia. MVEV is also responsible for occasional epidemics of encephalitis in eastern Australia. Since 1974, a number of sentinel chicken flocks have been established in Australia to provide an early warning of increased MVEV activity. These programs are supported by individual state health departments. Each state has a contingency plan that will be implemented if one or more chickens in a flock seroconverts to MVEV.

Currently, flocks are maintained in the north of Western Australia, the Northern Territory, New South Wales and in Victoria. The flocks in Western Australia and the Northern Territory are tested all year round but those in New South Wales and Victoria are tested only in the summer months, during the main MVEV risk season. Results are posted on the National Arbovirus Surveillance Website by state representatives. A yearly summary is presented in CDI (Commun Dis Intell 2010;34(3):225–240).

**References**